Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Efficacy and Safety Study of Lipid-Lowering Effects of XueZhiKang (XZK) in Patients With Hyperlipidemia

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Beijing Peking University WBL Biotech Co., Ltd.
ClinicalTrials.gov Identifier:
NCT01327014
First received: March 30, 2011
Last updated: July 22, 2014
Last verified: July 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: December 2012
  Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)